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obscure the onset, and delay the diagnosis of, toxo-
plasmosis. 
The aim of this study was to assess whether HN-in-
fected patients with cerebral toxoplasmosis can have 
demyelinating lesions that could be responsible for 
neurological dysfunction. Demyelination was inves-
tigated by evaluating cerebrospinal fluid (CSF) lev-
els of myelin basic protein (MBP), which represent 
a sensitive marker of active myelin breakdown, in 
both HN-seronegative and HN-seropositive individ-
uals [4,5]. We studied 16 AIDS patients with cere-
bral toxoplasmosis diagnosed on the basis of clinical 
presentation, computed tomography (CT) or magnetic 
resonance imaging (MRI) scans, Toxoplasma serology 
and response to treatment. Fourteen HN-seropositive 
individuals without evidence of neurological involve-
ment and nine HN-seronegative individuals with other 
non-demyelinating diseases were included as controls. 
MBP concentration in CSF was performed by a com-
petitive double-antibody radioimmunoassay (Diagnos-
tic System Laboratories, Webster, Texas, USA), as pre-
viously described [4]. Values greater than 4ng/ml 
were considered elevated, in accordance with the man-
ufacturer's instructions. As shown in Fig. 1, raised 
levels of MBP were found in CSF of seven out of 
16 (43.7%) patients with cerebral toxoplasmosis, while 
levels were within the normal range in the other nine 
patients (56.2%). Furthermore, in four of the seven in-
dividuals with CSF MBP elevation MRI showed multiple 
foci of demyelination in the periventricular whitemat-
ter of both cerebral hemispheres in addition to the 
characteristic contrast-enhancing lesions. No evidence 
of MBP elevation was observed in CSF of the controls. 
Our results indicate that HN-infected patients with 
cerebral toxoplasmosis may develop a demyelinating 
process, as determined by the findings of elevated 
MBP levels in CSF. MBP release may depend on the 
acute myelin breakdown due to necrotizing lesions of 
Toxoplasma gondii. However, since MBP elevation in 
CSF has been found in only 44% of patients, we be-
lieve that additional factors not directly related to tox-
oplasmosis may contribute to the development of de-
myelination. In this respect, the role of HN and other 
neurotropic viruses or indirect immunological mecha-
nisms associated with cytokine involvement should be 
taken into consideration. 
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Fig. 1. Cerebrospinal fluid of myelin basic protein (MBP) concen-
trations in patients with central nervous system (CNS) toxoplas-
mosis and control subjects. 
The neurological consequences and the pathological 
implications of HN- related demyelination that occur in 
cerebral toxoplasmosis remain to be established. Nev-
ertheless, since white matter involvement can present 
itself before, during and/or after CNS toxoplasmosis, 
the detection of active myelin breakdown by assess-
ment of CSF MBP should be performed systematically 
in HN-infected individuals with progressive neurologi-
cal impairment. 
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Retinal microvascular abnormalities in patients with AIDS-related complex or Iymphadenopathy syndrome 
Ocular microangiopathic syndrome is a common find-
ing in patients with AIDS. The most frequent manifes-
tation of retinal microvascular abnormalities in pa-
tients with HN-1 are cotton-wool spots [1]. Other 
microvascular abnormalities include retinal haemor-
rhages, ectasia of conjunctival vessels, and conjunc-
tival blood-flow sludging [2,3]. In 43.3% of patients 
with AIDS, and 8.8% of patients with AIDS-related 
complex (ARC), ophthalmoscopically visible micro-
vascular lesions were observed [4]. Retinal HN-1-re-
lated microvascular abnormalities are similar to those 
seen in diabetes mellitus, or systemic lupus erythe-
matosus. 
Fundus fluoresceinangiography in AIDS patients shows 
microaneurysms, teleangiectasis, focal areas of non-
perfusion with capillary drop-out and focal leakage 
[5]. However, fundus fluoresceinangiography was not 
performed in patients with ARC or lymphadenopathy 
syndrome (lAS). Therefore, we performed fluores-
ceinangiographic studies of the eye in patients with 
lAS or ARe. 
Fundus fluoresceinangiography was performed us-
ing a scanning laser ophthalmoscope (Rodenstock 
Inc., Munich, Germany) under standard conditions in 
four homosexual men. Three patients were staged 
lAS (Walter Reed stage 3), and one patient ARC 
(Walter Reed stage 4). Absolute CD4 + lymphocyte 
count was determined by FACScan (Becton-Dickin-
son, Heidelberg, Germany), and plasma fibrinogen 
levels by the method according to Clauss [6]. No 
microvascular abnormalities were observed on indi-
rect ophthalmoscopy after dilating pupils in any of the 
patients (eight eyes). Fluoresceinangiography demon-
strated retinal microaneurysms in the area around the 
four major branches of the central retinal artery in all 
eight eyes. In one patient additional microaneurysms 
were seen in the posterior pole (Table 1). No focal 
areas of non-perfusion with capillary drop-out and fo-
calleakage were observed in the four patients. These 
fluoresceinangiographic findings were similar to those 
in very early diabetic retinopathy [7]. 
Table 1. Clinical staging, absolute C04 + Iymphocyte count (x 106/ 1), 
plasma fibrinogen concentration and results of fundus f1uoresceinangio-
graphy. 
Clinical Absolute Fibrinogen Fluorescein-
Patient staging' C04+ count (mgldll angiography 
1 LAS/3 390 244 PM 
3 LAS/3 300 278 PM 
2 LAS /3 250 298 PM 
4 ARC/4 200 331 CPM 
'AIOS-related complex (ARC) or Iymphadenopathy syndrome (LAS)/Walter 
Reed stage. PM, peripheral microaneurysms; CPM, central and peripheral 
microaneurysms. 
Our results show that retinal microvascular abnor-
malities can occur in HN-l-infected patients with-
out cotton-wool spots and haemorrhages. Microa-
neurysms can be visible in patients with symptomatic 
HN-l infection staged lAS or ARe. Elevated fibrino-
gen levels were reported for patients with HIV-l in-
fection and cotton-wool spots [3]. Fibrinogen levels 
were within normal limits in all four patients (normal 
values for healthy control, 150-350 mg/d!), but there 
was a trend towards elevated levels with progression 
of HIV-l infection. 
HN-l-infected individuals are at increased risk of cere-
brovaseular aecidents, most often due to occlusion of 
small vessels [8]. Post-mortem series also suggest 
cerebral vascular abnormalities [8] . HMPAO-SPECT 
(Siemens Ine. , Münieh, Germany) studies suggest cere-
bral blood flow abnormalities in patients with HIV 
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infection and AIDS [10-12]. Close associations be-
tween ocular mierovaseular abnormalities and cerebral 
hypoperfusion or cognitive dysfunction were reported 
[13,14], while HMPAO-SPECT (Siemens Inc.) studies 
suggest a redueed cerebral blood flow in early stages 
of HIV-l infection [11]. Our results may be in accor-
dance with this finding beeause they suggest that reti-
nal microvascular abnormalities in HIV-l-infected pa-
tients are not restricted to patients in more advanced 
stages of HIV-l infection or full-blown AIDS. 
Retinal or cerebral microvaseular abnormalities in pa-
tients with HIV-l infection might be more eommon 
than previously expected. HIV-l-related microangio-
pathic alterations should be added to a list of indi-
rect faetors that might contribute to the pathogen-
esis of neurologie and neuro-ophthalmic abnormali-
ties in patients with HIV-l infection [15]. In addition, 
the analogy between HIV-l-related microangiopathic 
syndrome and diabetic retinopathy requires further 
consideration. The underlying conditions resulting in 
HIV-l-related mieroangiopathic syndrome need to be 
elucidated. 
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Three-year follow-up of asymptomatic HIV-infected men receiving combination zidovudine and acyclovir 
Combination of other antiviral drugs with zidovudine 
(ZDV) has been proposed to improve clinical efficacy 
and delay viral resistance. Acyclovir (ACV) and ZDV 
have been evaluated in a number of studies [1-7]. 
ACV is of particular interest because of its activity 
against some herpesviruses, which may cause disease 
in HN-infected individuals and could theoretically act 
as cofactors for disease progression [8]. Although sev-
eral investigators have not found that this combina-
tion (compared to ZDV alone) resulted in a greater 
improvement in laboratory parameters such as p24 
antigen [2,5], this combination may still reduce the fre-
quency of certain opportunistic infections or improve 
long-term prognosis. One recent study of patients with 
AIDS or AIDS-related complex (ARC) concluded that 
addition of high-dose ACV cotherapy to ZDV resulted 
in significant improvement in survival with minimal in-
crease in toxicity [6]. Since most studies of ZDV and 
ACV were in individuals with AIDS or ARC, additional 
data are needed for asymptomatic HN-infected indi-
viduals who may require therapy for many years. 
Twenty asymptomatic, HN-positive homo sexual men 
received ZDV and ACV in an open-Iabeled pilot study, 
as described in our initial report of the first 24 weeks 
[9]. We now present data from 3 years of follow-up. 
This study evaluated safety and tolerance of two regi-
mens, given in five divided doses per day: 500 mg ZDV 
plus 2000mg ACV daily (500 ZDV/2000 ACV) , and 
500 mg ZDV plus 4000 mg ACV daily (500 ZDV /4000 
ACV). Moderate side-effects or laboratory abnormal-
ities resulted in 40% dose reduction. Therapy was 
discontinued for more severe clinical or laboratory 
abnormalities. 
Of the 10 men receiving 500 ZDV/2000 ACV, one was 
diagnosed with non-Hodgkin's lymphoma (week 7), 
and another with Kaposi's sarcoma (week 144). All 
other men remained free of AIDS and completed the 
study. One man required dose reduction (week 63) 
because of myalgias and an increased creatine kinase 
(CK = 1387U/l). 
Of the 10 men receiving 500 ZDV/4000 ACV, one 
was diagnosed with candida esophagitis at approxi-
mately week 8 and another (on reduced doses) de-
veloped Pneumocystis carinii pneumonia (week 63). 
Four others withdrew from the study (at weeks 10, 
10, 36 and 129), because of symptoms such as nau-
sea, malaise and fatigue. Dose reduction was required 
for five men suffering from nausea or anorexia (two 
men), myalgias with an elevated CK (663 U/l) (one 
man), anemia (hemoglobin, 11.6g/dl) (one man) and 
neutropenia (0.93 x 109) (one man). These last two 
men were subsequently returned to full doses without 
further hematologic toxicity. 
Table 1 shows hematologic parameters for 15 men 
who remained in the study and without AIDS for 52 
weeks, 14 men followed for 104 weeks, and 12 men 
who completed the study. If results for a specific week 
were missing, the value was interpolated based on pre-
ceding and subsequent weeks. The greatest changes 
were noted for red blood cell count (RBC) and mean 
corpuscular volume (MCV); changes were most Pro-
nounced during the first 26 weeks. 
Table 1. Mean hematologic values among asymptomatic HIV-inlected men completing at least 52 weeks 01 combination therapy with zidovudine and 
acyclovir. 
Week 
Laboratory test Baseline (n = 15) 10 (n = 15) 26 (n = 15) 52 (n = 15) 104 (n = 14) Conclusion (n = 12) 
Red blood count (x 1012) 5.07 4.30 4.13 4.09 4.02 4.04 
Serum hemoglobin (g/dl) 14.8 14.1 14.8 14.8 14.8 14.6 
Mean corpuscular volume (11) 87 96 106 105 106 105 
Neutrophils (x 109) 3.19 2.47 2.84 2.67 2.85 3.17 
Total Iymphocytes (x 109) 2.06 1.99 1.94 2.00 2.24 2.11 
CD4 + count (x 106) 538 505 557 610 522 497 
Monocyte (x 109) 0.42 0.37 0.43 0.41 0.40 0.40 
Platelets (x 106) 276400 293355 292630 278095 274606 283500 
